New insights into sexual dimorphism during progression of heart failure and rhythm disorders

Endocrinology

Volumn 151, Issue 4, 2010, Pages 1837-1845

  Thireau, Jérôme ^a   Aimond, Franck ^b   Poisson, Denise ^a   Zhang, Beili ^a   Bruneval, Patrick ^c   Eder, Véronique ^d   Richard, Sylvain ^b   Babuty, Dominique ^a  

^a UNIVERSITÉ DE TOURS   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d SERVICE DE DERMATOLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; NEUROHORMONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; HEART ARRHYTHMIA; HEART CONDUCTION; HEART FAILURE; HEART FUNCTION; HISTOPATHOLOGY; MALE; MOUSE; NONHUMAN; PARAMETER; PRIORITY JOURNAL; QRS COMPLEX; SEX DIFFERENCE; WILD TYPE;

ACTION POTENTIALS; ANIMALS; ARRHYTHMIAS, CARDIAC; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; FIBROSIS; HEART; HEART CONDUCTION SYSTEM; HEART FAILURE; KAPLAN-MEIERS ESTIMATE; MALE; MICE; MICE, TRANSGENIC; ORCHIECTOMY; OVARIECTOMY; PATCH-CLAMP TECHNIQUES; RECEPTORS, ADRENERGIC, BETA-2; SEVERITY OF ILLNESS INDEX; SEX CHARACTERISTICS; STATISTICS, NONPARAMETRIC;

EID: 77950240196     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2009-1184     Document Type: Article

References (32)

1. Mehta PA, Cowie MR 2006 Gender and heart failure: a population perspective. Heart 92(Suppl 3):iii14-iii18
2. Cleland JG, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, van Gilst WH, Widimsky J, Freemantle N, Eastaugh J, Mason J 2003 The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 24:442-463
3. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D 1999 Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol 33:1948-1955
4. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E, Wenger N 2002 Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288:49-57
5. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M 2003 Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349:523-534
6. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E 1998 Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 280:605-613
7. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333
8. Malkin CJ, Pugh PJ, West JN, van Beek EJ, Jones TH, Channer KS 2006 Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J 27:57-64
9. Milano CA, Allen LF, Rockman HA, Dolber PC, McMinn TR, Chien KR, Johnson TD, Bond RA, Lefkowitz RJ 1994 Enhanced myocardial function in transgenic mice overexpressing the β2-adrenergic receptor. Science 264:582-586
10. Gao XM, Agrotis A, Autelitano DJ, Percy E, Woodcock EA, Jennings GL, Dart AM, Du XJ 2003 Sex hormones and cardiomyopathic phenotype induced by cardiac β2-adrenergic receptor overexpression. Endocrinology 144:4097-4105
11. Cross HR, Murphy E, Koch WJ, Steenbergen C 2002 Male and female mice overexpressing the β(2)-adrenergic receptor exhibit differences in ischemia/reperfusion injury: role of nitric oxide. Cardiovasc Res 53:662-671
12. Fornes P, Heudes D, Simon D, Guillemain R, Amrein C, Bruneval P 1996 Influence of acute or chronic rejection on myocardial collagen density in serial endomyocardial biopsy specimens from cardiac allografts. J Heart Lung Transplant 15:796-803
13. Thireau J, Zhang BL, Poisson D, Babuty D 2008 Heart rate variability in mice: a theoretical and practical guide. Exp Physiol 93: 83-94
14. VanderBrink BA, Link MS, Aronovitz MJ, Saba S, Sloan SB, Homoud MK, Estes III IN, Wang PJ 1999 Assessment of atrioventricular nodal physiology in the mouse. J Interv Card Electrophysiol 3:207-212
15. Brunet S, Aimond F, Li H, Guo W, Eldstrom J, Fedida D, Yamada KA, Nerbonne JM 2004 Heterogeneous expression of repolarizing, voltage-gated K+ currents in adult mouse ventricles. J Physiol 559: 103-120
16. Dorn 2nd GW, Robbins J, Sugden PH 2003 Phenotyping hypertrophy: eschew obfuscation. Circ Res 92:1171-1175
17. Adams Jr KF, Sueta CA, Gheorghiade M, O'Connor CM, Schwartz TA, Koch GG, Uretsky B, Swedberg K, McKenna W, Soler-Soler J, Califf RM 1999 Gender differences in survival in advanced heart failure. Insights from the FIRST study. Circulation 99:1816-1821
18. Furman RH 1968 Are gonadal hormones (estrogens and androgens) of significance in the development of ischemic heart disease.Ann NY Acad Sci 149:822-833
19. 1996 Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation 93:1043-1065
20. Kawara T, Derksen R, de Groot JR, Coronel R, Tasseron S, Linnenbank AC, Hauer RN, Kirkels H, Janse MJ, de Bakker JM 2001 Activation delay after premature stimulation in chronically diseased human myocardium relates to the architecture of interstitial fibrosis. Circulation 104:3069-3075
21. Kashani A, Barold SS 2005 Significance of QRS complex duration in patients with heart failure. J Am Coll Cardiol 46:2183-2192
22. Kääb S, Nuss HB, Chiamvimonvat N, O'Rourke B, Pak PH, Kass DA, Marban E, Tomaselli GF 1996 Ionic mechanism of action potential prolongation in ventricular myocytes from dogs with pacinginduced heart failure. Circ Res 78:262-273
23. Petkova-Kirova PS, Gursoy E, Mehdi H, McTiernan CF, London B, Salama G 2006 Electrical remodeling of cardiac myocytes from mice with heart failure due to the overexpression of tumor necrosis factor-α. Am J Physiol Heart Circ Physiol 290:H2098-H2107
24. Grandy SA, Denovan-Wright EM, Ferrier GR, Howlett SE 2004 Overexpression of human β2-adrenergic receptors increases gain of excitation-contraction coupling in mouse ventricular myocytes. Am J Physiol Heart Circ Physiol 287:H1029-H1038
25. An R, Heath BM, Higgins JP, Koch WJ, Lefkowitz RJ, Kass RS 1999 β2-Adrenergic receptor overexpression in the developing mouse heart: evidence for targeted modulation of ion channels. J Physiol 516(Pt 1):19-30
26. Spach MS, Dolber PC, Heidlage JF 1988 Influence of the passive anisotropic properties on directional differences in propagation following modification of the sodium conductance in human atrial muscle. A model of reentry based on anisotropic discontinuous propagation. Circ Res 62:811-832
27. Cavasin MA, Tao ZY, Yu AL, Yang XP 2006 Testosterone enhances early cardiac remodeling after myocardial infarction, causing rupture and degrading cardiac function. Am J Physiol Heart Circ Physiol 290:H2043-H2050
28. Marsh JD, Lehmann MH, Ritchie RH, Gwathmey JK, Green GE, Schiebinger RJ 1998 Androgen receptors mediate hypertrophy in cardiac myocytes. Circulation 98:256-261
29. Li Y, Kishimoto I, Saito Y, Harada M, Kuwahara K, Izumi T, Hamanaka I, Takahashi N, Kawakami R, Tanimoto K, Nakagawa Y, Nakanishi M, Adachi Y, Garbers DL, Fukamizu A, Nakao K 2004 Androgen contributes to gender-related cardiac hypertrophy and fibrosis in mice lacking the gene encoding guanylyl cyclase-A. Endocrinology 145:951-958
30. Babiker FA, De Windt LJ, van Eickels M, Thijssen V, Bronsaer RJ, Grohé C, van Bilsen M, Doevendans PA 2004 17β-Estradiol antagonizes cardiomyocyte hypertrophy by autocrine/paracrine stimulation of a guanylyl cyclase A receptor-cyclic guanosine monophosphate-dependent protein kinase pathway. Circulation 109:269-276
31. Dubey RK, Gillespie DG, Jackson EK, Keller PJ 1998 17β-Estradiol, its metabolites, and progesterone inhibit cardiac fibroblast growth. Hypertension 31:522-528
32. Pedram A, Razandi M, Lubahn D, Liu J, Vannan M, Levin ER 2008 Estrogen inhibits cardiac hypertrophy: role of estrogen receptor-βto inhibit calcineurin. Endocrinology 149:3361-3369